Teva Pharmaceutical (NYSE:TEVA) is reportedly closing its sterile injectables plant in Godollo, Hungray and 500 workers could lose their jobs. The generics-maker is slated to close or sell the facility by the end of 2018.
The plant stopped production last year after the FDA found an array of sterility issues that the agency said put the plant’s drugs at risk of contamination. Later, the FDA added the facility to its import alert list, which banned all but 2 of its drugs.
Get the full story at our sister site, Drug Delivery Business News.
The post Teva to cut 500 jobs after closing Hungary facility appeared first on MassDevice.
from MassDevice http://ift.tt/2r0stfc
Cap comentari:
Publica un comentari a l'entrada